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A synthetic DNA-binding domain guides distinct chromatin-
modifying small molecules to activate an identical gene network 
Le Hana,b‡, Ganesh N. Pandianc‡, Anandhakumar Chandrana, Shinsuke Satoc, Junichi Taniguchia, 
Gengo Kashiwazakia, Yoshito Sawatania, Kaori Hashiyaa, Toshikazu Bandoa, Yufang Xub, Xuhong 
Qianb, and Hiroshi Sugiyamaa,c
Abstract: Synthetic dual-functional ligands targeting specific DNA 
sequences and histone-modifying enzymes could achieve regulatory 
control over multi-gene networks in living cells. Unlike the broad 
array of targeting small molecules for histone deacetylases (HDACs), 
a few modulators are known for histone acetyltransferases (HATs) 
playing a central role in transcriptional control. As a novel chemical 
approach to induce selective HAT-regulated genes, we conjugated a 
DNA-binding domain (DBD) `I` with N-(4-chloro-3-trifluoromethyl-
phenyl)-2-ethoxy-benzamide (CTB), an artificial HAT activator. Using 
in vitro enzyme activity assays and microarray studies, here we 
demonstrate that the distinct functional small molecules could be 
transformed to have identical bioactivity when conjugated with a 
targeting DBD. This proof-of-concept synthetic strategy validates the 
switchable functions of HDAC and HAT in gene regulation and 
provides a molecular basis for developing versatile bioactive ligands. 
Acetylation of histones is the critical event in transcriptional 
regulation and gets maintained in an equilibrium state by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs).1 
Small molecules inhibitors for HDACs can induce global 
changes in the acetylation profile but in a sequence-independent 
manner.2 We previously synthesized a class of sequence-
specific small molecules called SAHA-PIPs comprising the 
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and 
selective DNA-binding pyrrole–imidazole polyamide (PIP)(s). 
The biological evaluation showed that SAHA-PIP could induce 
particular gene networks in mouse and human somatic cells.3-6 
We showed site-specific inhibition of HDACs and subsequent 
acetylation of histones as the mechanism behind the distinctive 
gene-activating ability of SAHA–PIP.7 Transcriptionally 
permissive marks are acquired more reliably by activating the 
epigenetic writers like HATs than by blocking the erasers.8 The 
CREB-binding protein (CBP)/p300 family are global 
transcriptional co-activating HATs that act as the master 
regulators of gene expression and play essential roles in cell 
cycle control, differentiation, and apoptosis.9,10 Several small 
molecules are known as acetylation inhibitors.11 In contrast, only 
a few HAT activators like Pentadecylidenemalonate, N- (4-
chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide (CTB), 
Nemorosone, and TTK21 are known.12  
Considering the essential role of HAT in gene regulation, we 
chose to confer selectivity to the cell permeable HAT activator 
CTB by conjugating it with PIP. Recently, SAHA–PIP `I` or 
SAHA-I (Figure 1) was shown to target OCT-3/4 and turn on the 
HDAC1-repressed core pluripotency genes.7 The HATs 
p300/CBP-interacting protein are known to be the critical 
components of the pluripotency gene network.13 As an 
innovative approach to induce HAT-regulated genes, we 
conjugated the same predesigned DNA sequences in `I` with 
CTB to synthesize CTB-PIP-I or CTB-I. NH2-CTB or CTB was 
synthesized by following previously published procedures 
(Scheme S1).10 However, NH2-CTB was not suitable for the 
solid-phase synthesis as the coupling monomer required 
carboxylic acid. For this reason, HO2C-CTB that can be 
synthesized by coupling CTB and adipic acid, was devised to 
optimize the synthesis of CTB-PIP conjugates (Scheme 1) and 
their purification (Figure S1). Cytotoxicity studies showed that 
unlike SAHA that kills 50% of cells at 1 µM concentration, CTB 
and CTB-I had no effect on HDF cells even at 5 µM (Figure S2). 
Scheme 1. (A). Structure of SAHA-I, (B) Synthetic Scheme for CTB-I. General 
conditions: (i) 3-dimethylaminopropylamine (Dp), 45oC, 3h and (C) Structure of 
CTB analogue conjugate (CTB-Ne-I). 
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     Biological evaluation of the CTB-I was done using microarray 
with appropriate controls (CTB, SAHA, and SAHA-I) in the 
conditions optimized7 and according to preliminary studies. CTB-
I remarkably activated an identical cluster of genes like SAHA-I 
in HDFs (Figure 1A, CTB-I, and SAHA-I). CTB activated about 
12 genes, and SAHA activated a different set of 17 genes 
(Figure 1A and B, CTB and SAHA). CTB-I and SAHA-I activated 
about 26 and 40 genes, respectively, including 24 common 
genes (Figure 1B, CTB-I, and SAHA-I). Interestingly, neither 
CTB nor SAHA shared any genes with each other or with CTB-I 
and SAHA-I. The scatter plot of the upregulated transcripts in 
CTB-I-treated HDFs (>2-fold; p < 0.05) produced a strong linear 
correlation (R2 = 0.95) with SAHA-I (Figure 1C) than that with 
CTB-treated HDFs (R2 = 0.37) (Figure 1D).  
 
Figure 1. (A) A heat map based on the unsupervised hierarchical clustering 
analysis of the expression data derived from 4 wells for the top 138 genes in 
DMSO-, CTB-, SAHA–I-, and CTB-I-treated HDFs (>10-fold and p < 0.05). (B) 
A four-circle Venn diagram from the data (>5-fold and p < 0.05) showed that 
the number of genes upregulated in effector treated HDFs. (C) Scatter plot of 
the data (>2-fold and p < 0.05) show a high correlation (R
2
 = 0.95) between 
replicate samples of CTB-I and SAHA-I treated HDFs to suggest similar 
targets. (D) Conversely, a plot of CTB-I-treated HDFs vs. CTB-treated HDFs 
showed a relatively weak correlation (R
2
 = 0.37) to suggest distinct bioactivity.   
      CTB-I favored transcriptional activation over repression 
because 48 genes got upregulated, and 19 genes were 
downregulated (Table S1). Thus, conjugation of PIP markedly 
altered and boosted the bioactivity of both CTB and SAHA by 2-
fold and directed them to identical gene network(s). Analysis of 
the upstream effectors showed that both SAHA-I and CTB-I 
activated OCT-3/4 regulated pluripotency genes (Figure 2A). 
QRT-PCR analysis validated the expression of the genes 
identified in Figure 2A, and the endogenous expression of OCT-
3/4 was significantly (P < 0.05) induced by more than 50-fold in 
both SAHA–I and CTB-I treated HDFs. CTB-I also significantly 
(P< 0.05) induced SOX2, NANOG, LIN28B, EPCAM, and SALL4 
and markedly upregulated ZIC3 and DPPA4 (Figure 2B-I). This 
report is the first to show that directed HAT activity trigger the 
activation of key pluripotency genes and microRNAs like 
MIR302C14 (Figure S3). 
 
Figure 2. (A) Analysis of the upstream regulators from the summary of data 
obtained from 4 wells show that like SAHA-I7, CTB–I activate the OCT-3/4 
pathway. QRT-PCR analysis of (B) OCT-3/4, (C) SOX2, (D) NANOG, (E) 
LIN28B, (F) SALL4, (G) EPCAM, (H) ZIC3 and (I) DPPA4 in the effectors 
(CTB, CTB-I and SAHA-I) treated HDFs. Mean ± SD from 18 wells, p < 0.05 (6 
biological replicates). (J) ChIP-seq analysis after immunoprecipitation with 
H3K14ac antibody show hyperacetylation in the promoter and transcribed 
regions of OCT-3/4 like SAHA-I7 (Enlarged and indicated).  
    
      CTB-I and SAHA-I displayed similar gene expression profiles 
and suggested a common mechanism. To clarify the mode of 
action, we synthesized a CTB analogue conjugate termed CTB-
Ne-I where the relative position of –CF3 and –Cl in CTB is 





changed to lack HAT activity according to Kundu and 
coworkers.10 (Scheme S1c). A HAT activity study in HDF cells 
showed that CTB-I retained the HAT activity of CTB as HAT 
activity got significantly increased in CTB and CTB-I-treated 
HDFs when compared to that treated with an inactive CTB-Ne-I 
(Figure S4). SAHA-I showed only a mild increase in HAT activity 
to suggest the indirect effect caused by HDAC inhibition. This 
pattern was further substantiated through the enzymatic activity 
assay study carried out in HeLa nuclear extract where only CTB 
and CTB-I significantly increased HAT activity when compared 
to SAHA-I and CTB-Ne-I (Figure S5). Unlike CTB-I and SAHA-I, 
the inactive analogue CTB-Ne-I did not upregulate the 
pluripotency genes to validate the need for CTB-mediated HAT 
activity in gene induction (Figure S6). An HDAC activity assay in 
cells treated with individual effectors precluded HDAC inhibitory 
activity of CTB as the possible gene induction mechanism as 
only SAHA and SAHA-I resulted in HDAC inhibition in cells  
(Figure S7). In vitro assay carried out with the nuclear extracts 
from HeLa cells and HDFs further validated this pattern (Figure 
S8). Chromatin immunoprecipitation (ChIP)-seq analysis 
revealed hyperacetylation in the transcribed regions of OCT-3/4 
in CTB-I-treated HDFs than in DMSO-treated HDFs (Figure 2J). 
Interestingly, like SAHA-I, CTB-I also resulted in the enrichment 
in the acetylation level of H3K14 (Figure S9). Also, peaks 
around the putative promoter region having `I` binding site were 
identical in CTB-I and SAHA-I-treated HDFs (Figure 2J (box)).  
 
      Recently, high-throughput sequencing studies substantiated 
the strong binding affinity of PIP15, and in accordance with gene 
expression pattern; SAHA-I had superior binding specificity 
toward the promoter sequence of human OCT-3/47 than the 
germ cell gene PIWIL15. The in vitro binding association and 
ChIP-PCR studies verified that the pattern observed in the 
model oligonucleotide duplex can be extrapolated to the 
corresponding sequence within the chromatin.7 CTB-I also 
triggered hyperacetylation marks in NANOG, SOX2, DPPA4, 
EPCAM, LIN28, and ZIC3 (Figure S10), however, none had the 
notable acetylation profile observed in the promoter and 
transcribed regions of OCT-3/4. CTB-I did not show a marked 
difference in the acetylation pattern observed in the germ cell 
genes (PIWIL1 and TDRD1) and the housekeeping gene 
(GAPDH and HMGB1)(Figure S11). The top five significantly 
enriched pathways verified the CTB-I effect on the expression of 
the key pluripotency genes (Table S2, CTB-I treated HDFs). 
CTB induced an entirely different set of genes associated with 
liver X receptor (LXR) (Table S2, CTB treated HDFs). HDAC1 
and p300 bind directly to the overlapping regions of the histone 
H3 tail and compete with each other.16 HDAC1 is known to 
regulate the pluripotency and lineage-specific transcriptional 
network.17 The combination of CTB-I and SAHA-I resulted in the 
expression of OCT-3/4, which has a similar expression profile 
attained with their individual treatment (Figure S12). Because 
p300 can acetylate HDAC1 upon activation and attenuate its 
deacetylase activity, these two synthetic histone-modifiers could 
be inducing a similar pattern of gene expression. Although the 
actual mechanism underlying the identical bioactivity is not 
straightforward, site-specific acetylation triggered by SAHA-
mediated HDAC inhibition or CTB-mediated HAT activation at a 
particular key sequence could be causing the activation of OCT-
3/4 and its regulated genes.  
 
     Considering the importance of HATs in the multi-gene 
network associated cell biological processes, our study could 
open new opportunities to modulate HAT-regulated gene(s). 
CTB-I displayed similar HAT activity pattern in HeLa cells as 
HDFs to suggest the potential of this strategy in p300 deficient 
cells. Since the achievement of chemically induced pluripotent 
stem cells18, bioactive ligands aiding cellular reprogramming are 
in rising demand. Our synthetic strategy could be harnessed to 
probe the functional interplay between the histone-modifying 
enzymes in co-ordinating the therapeutically important genes. 
Tuning of the functional module19 and expansion of the 
recognition ability20 could lead to the construction of robust 
epigenetic switches with versatile bioactivity.  
Experimental Section 
Experimental details are shown in the supporting information. 
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Distinct to Identical - A Chemical Transformation. A novel conjugation of selective DNA-binding 
`I` with N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide (CTB), a histone acetyltransferase 
(HAT) activator yielded an epigenetic switch with bioactivity identical to the distinct operative histone 
deacetylase (HDAC) inhibiting SAHA-I. 
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       General: All chemical reagents and solvents were obtained from commercial sources and used without 
further purification. 1H NMR were recorded on a JEOL JNM ECA-600 spectrometer with chemical shifts expressed 
as ppm (Me4Si as 0ppm). The purities were analyzed on JASCO Engineering PU-2089 plus series system with 
detection at 254 nm, equipping a Shimadzu LC-10AD liquid chromatograph pump, an SPD-10A UV/vis detector, and 
a Chemcobond 5-ODS-H reversed-phase column (4.6 × 150 mm). A gradient of 0-100% acetonitrile and 0.1% TFA 
in water at a flow rate of 1.0 mL/min over 40 min was used as eluent. HPLC purification was performed with a 
JASCO CCPS HPLC pump, a JASCO UV8020 HPLC UV/vis detector, and a Chemcobond 5-ODS-H reversed-phase 
column (10 × 150 mm) in 0.1% TFA in water with CH3CN as eluent at a flow rate of 1.0 mL/ min, and a linear 
gradient elution of CH3CN with detection at 254 nm. ESI-TOFMS was produced on a BioTOF II (Bruker Daltonics) 
mass spectrometer using a positive ionization mode. UV spectra were measured on a Nanodrop ND-1000 
spectrophotometer. The biological experiments were only employed on compounds whose purity is at least 95%. 
 
Scheme S1. Synthetic Scheme for NH2-CTB and CTB1 
 
General conditions: (i) sulfuric acid, methanol, reflux, overnight; (ii) iodoethane, K2CO3, N,N-dimethylformamide, 60 
oC, 2 h; (iii) LiOH·H2O, H2O/MeOH, overnight at RT; (iv) HCTU, N,N-diisopylethylamine, 
N,N-dimethylformamide, overnight at RT; (v) H2, Pd/C, ethyl acetate, 6 h at RT. 
 
 3 
Synthesis of CTB unit for P-I conjugates 
 
 
 To a solution of compound 5-nitrosalcylic acid (1 g, 5.46 mmol) in DMF (15 mL) were added K2CO3 (4.52 g, 32.8 
mmol) and iodoethane (2.2 ml, 27.5 mmol). The reaction mixture was stirred for 6 h at 50 °C. Evaporation of the 
solvent gave a yellow residue, which was filtrated with water (20 mL) to produce 1 (955 mg, 3.99 mmol, 73%) as a 
yellow powder. 
1 : 1H NMR (600 MHz, CDCl3) δ 8.67 (d, J = 2.7 Hz, 1H; Ar-H), 8.33 (dd, J = 2.7, 9.6 Hz, 1H; Ar-H), 7.02 (d, J = 
9.6 Hz, 1H; Ar-H), 4.39 (q, J = 7.3 Hz, 2H; CH2), 4.23 (q, J = 7.3 Hz, 2H; CH2), 1.52 (t, J = 7.3 Hz, 3H; CH3), 1.41 (t, 
J = 7.3 Hz, 3H; CH3)  
 
 
 To a solution of compound 1 (950 mg, 3.99 mmol) in water (15 mL) were added NaOH (1 g, 25 mmol). The 
reaction mixture was stirred for 15 h at 40 °C. Atfter the filtration, quenching of the solvent by diluted HCl gave a 































































rt = 15.1 min rt = 23.5 min HPLC : 0-100% 0.1%TFA-CH3CN, 40 min
73%







rt = 16.5 minrt = 23.5 min
1 287%
15 h, 40 °C
HPLC : 0-100% 0.1%TFA-CH3CN, 40 min
 4 
2 : 1H NMR (600 MHz, CDCl3) δ 9.06 (d, J = 2.8 Hz, 1H; Ar-H), 8.44 (dd, J = 2.8, 8.9 Hz, 1H; Ar-H), 7.16 (d, J = 
8.9 Hz, 1H; Ar-H), 4.45 (q, J = 6.9 Hz, 2H; CH2), 1.64 (t, J = 6.9 Hz, 3H; CH3) 
 
 
 To a solution of compound 2 (733 mg, 3.47 mmol) in DMF (11 mL) were added HCTU (1.58 g, 3.82 mmol), 
diisopropyl amine (0.73 mL, 4.16 mmol). After the reaction solution was stirred for 10 min, 
5-amino-2-chlorobenzotrifluoride (680 mg, 3.47 mmol) were added. The reaction mixture was stirred for 14 h at 
25 °C. Evaporation of the solvent gave a yellow residue, which was filtrated with 5% HCl (20 mL), water (20 mL) to 
produce crude 3 (1.85 g, containing HCTU residue) as a brown powder.  
ESI-TOF-MS (positive) m/z calcd for C16H13ClF3N2O4+ [M+H]+ 389.0510; found 389.0527. 
 
 
  To a solution of compound 3 (500 mg, containing HCTU residue) in AcOEt (10 mL) were added 10% Pd-C (20 
mg). The reaction mixture was stirred for 16 h at rt under H2 gas (0.2 MPa). Atfter the celite filtration by 
CH2Cl2-MeOH, Evaporation of the solvent gave a brown residue 4 (387 mg, containing HCTU residue) as a white 
powder. Analytical HPLC tR = 20.8 min; 1H NMR (600 MHz, CDCl3): δ 10.45 (s, 1H), 7.99 (d, J = 2.8 Hz, 1H), 7.76 
(s, 1H), 7.60 (d, J = 2.7 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 6.87-6.83 (m, 2H), 4.21 (q, J = 6.9 Hz, 2H), 3.62 (br, 2H), 
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 To a solution of compound 4 (660 mg, containing HCTU residue) in DMF (7 mL) were added HCTU (820 mg, 1.98 
mmol), diisopropyl amine (0.41 mL, 2.38 mmol). The reaction mixture was stirred for 1 h at 25 °C. Evaporation of 
the solvent gave a brown residue, which was filtrated with 1N NaOH (20 mL) for the removal of HCTU residue, to 
produce crude 5 (580 mg, 1.13 mmol) as a light-brown powder. 
 
ESI-TOF-MS (positive) m/z calcd for C24H27ClF3N2O5+ [M+H]+ 515.1555; found 515.1127. 
 
 
	 To a solution of compound 5 (580 mg, 1.13 mmol) in water (20 mL) and EtOH (20 mL) were added NaOH (1 g, 
25 mmol). The reaction mixture was stirred for 2 h at 90 °C to change brown solution. Atfter the evaporation of 
EtOH, quenching of the solvent by diluted HCl gave a white precipitation, which was filtrated with water (10 mL) to 
produce 6 (503 mg, 1.04 mmol, 92%) as a white powder. 
6 : 1H NMR (600 MHz, d6-DMSO) δ 10.51 (s 1H; NH), 9.92 (s, 1H; NH), 8.33 (s, 1H; Ar-H), 7.95 (d, J = 8.9 Hz, 1H; 
Ar-H), 7.87 (d, J = 2.0 Hz, 1H; Ar-H), 7.72 (m, 2H; Ar-H x 2), 7.13 (d, J = 8.9 Hz, 1H; Ar-H), 4.13 (q, J = 6.9 Hz, 




































































rt =   20.7 min
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2 h, 90 °C 6


















This compound was synthesized as HO2C-CTB. 1H NMR (600 MHz, DMSO-d6): δ = 12.02 (s, 1H), 10.60 (s, 1H), 
10.00 (s, 1H), 8.84 (s, 1H), 8.27 (d, J = 1.0 Hz, 1H), 7.88 (dd, J = 8.9, 2.0 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.54 (d, 
J = 8.3 Hz, 1H), 7.27 (d, J = 9.6 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 2.31 (t, J = 7.2 Hz, 2H), 2.25 (t, J = 7.5 Hz, 2H), 
1.61 (m, 2H), 1.54 (m, 2H), 1.45 (t, J = 6.9 Hz, 3H). ESI-TOF-MS (positive) m/z calcd for C22H23ClF3N2O5+ [M+H]+ 




       The preparation of P-I polyamide-CTB conjugates by Fmoc solid-phase synthesis. All 
machine-assisted polyamide syntheses were performed on a PSSM-8 peptide synthesizer (Shimadzu, Kyoto) with a 
computer-assisted operation system at 43 mg of Fmoc-P-oxime resin (ca. 0.42 mmol/g, 100~200 mesh) by Fmoc 
solid-phase chemistry. Reaction cycles were as follows: deblocking steps for 4 min x 2, 20% piperidine in DMF; 
coupling step for 60 min, corresponding carboxylic acids, HCTU (88 mg), diisopropylethylamine (DIEA) (36 µL), 
1-methyl-2-pyrrolidone (NMP); washing steps for 1 min x 5, DMF. Each coupling reagents in steps were prepared in 
NMP solution of Fmoc-P-COOH (77 mg), Fmoc-I-COOH (77 mg), Fmoc-P-I-COOH (70 mg), Fmoc-β-COOH (66 
mg), Fmoc-γ-COOH (69 mg) and HO2C-CTB 6 (103 mg). All other couplings were carried out with single-couple 























































(by using 6) 3 h, 45 °C
rt =   21.9 min
CTB-I
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reaction vessel for 30 min. 2-mL plastic centrifuge tubes with loading Fmoc-monomers with HCTU in NMP 1 mL 
were placed in programmed position. All lines were washed with NMP after solution transfers. After the completion 
of the synthesis by the peptide synthesizer, the resin was washed with DMF (1 mL x 2), methanol (1 mL x 2), and 
dried in a desiccator at room temperature in vacuo. 
 
       CTB-β-PIIP-γ-PPPP-Dp (CTB-I). A dried sample resin was cleaved with 0.5 ml of 
3,3-dimethyaminopropylamine (Dp) for 3 h at 45 ºC. The reaction mixture was filtered, triturated from CH2Cl2-Et2O, 
to yield P-I polyamide as yellow crude powder (38 mg). The crude was purified by flash column chromatography 
(elution with trifluoroacetic acid and a 0-45% acetonitrile linear gradient (0-45 min) at a flow rate of 18 mL min-1 
under 254 nm) as white powder (13 mg).1H NMR (600 MHz, DMSO-d6): δ 10.50 (s, 1H), 10.38 (s, 1H), 10.25 (s, 
1H), 9.93 (s, 1H), 9.90 (s, 4H), 9.84 (s, 1H), 9.40 (s, 1H), 8.32 (s, 1H), 8.15 (t, J = 6.2 Hz, 1H), 8.09 (t, J = 5.5 Hz, 
1H), 7.95 (d, J = 7.6 Hz, 1H), 7.89 (t, J = 5.5 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.72 (dd, J = 8.9, 2.0 Hz, 1H), 7.70 
(d, J = 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.29 (s, 1H), 7.22 (s, 2H), 7.20 (s, 1H), 7.17 (s, 2H), 7.11 (d, J = 8.8 
Hz, 1H), 7.07 (s, 2H), 7.04 (s, 1H), 6.95 (s, 1H), 6.93 (s, 1H), 6.89 (s, 1H), 4.11 (q, J = 6.9 Hz, 2H), 4.011 (s, 3H), 
4.007 (s, 3H), 3.850 (s, 3H), 3.846 (s, 3H), 3.83 (s, 6H), 3.81 (s, 6H), 3.31 (m, 2H), 3.24 (m, 4H), 3.07 (m, 2H), 2.79 
(s, 3H), 2.78 (s, 3H), 2.42 (t, J = 6.9 Hz, 2H), 2.28 (m, 4H), 2.08 (t, J = 6.9 Hz, 2H), 1.84 (m, 2H), 1.80 (m, 2H), 1.54 
(m, 4H), 1.35 (t, J = 6.9 Hz, 3H) analytical HPLC tR = 22.0 min; ESI-TOF-MS m/z calcd for C80H94ClF3N24O142+ 
[M+2H]2+ 853.3505, found 853.3577. 
 
       CTB-Ne-β-PIIP-γ-PPPP-Dp (CTB-Ne-I.). 
        Synthesis of the inactive CTB analogue conjugate (CTB-Ne-I) was carried out with the same scheme as 
CTB-I. analytical HPLC tR = 15.3 min (linear gradient of 0-100% 0.1% TFA/MeCN over 20 min); ESI-TOF-MS m/z 
calcd for C80H94ClF3N24O142+ [M+2H]2+ 853.3505; found 853.3470. 
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Analytical Data of N-(4-chloro-3-(trifluoromethyl)phenyl)-2-ethoxybenzamide (CTB). Analytical HPLC 
tR = 31.8 min; ESI-TOF-MS m/z calcd for C16H13ClF3NO2+ [M+H]+ 344.0660, found 343.9595; purity: 95.3%. 1H 
NMR (600 MHz, CDCl3): δ 10.30 (s, 1H), 8.30-8.28 (m, 1H), 7.99 (s, 1H), 7.88 (s, 1H), 7.51-7.49 (m, 2H), 7.15-7.02 
(m, 2H), 4.32 (q, J = 6.9 Hz, 2H), 1.65 (t, J = 6.9 Hz, 3H). 
 
       Cell culture and optimization of parameters for treatment of CTB-PIP  
       HDF from 54-year-old Caucasian female were purchased from Cell Applications, Inc. We used these cells 
for the screening studies and maintained in Dulbecco's modified eagle medium (DMEM, Nacalai Tesque, Japan) 
containing 10% fetal bovine serum (FBS, Japan Serum) and 0.5% as mentioned before.2 HDF cells of P6 were 
trypsinized for 5 min at 37 °C, and were treated by the addition of 1 mM of each individual effectors (CTB, CTB-I, 
SAHA-I and SAHA) to achieve a final polyamide concentration of 1 µM in 0.5% DMSO and then were incubated in 
a 5% CO2 atmosphere at 37 °C for 48 h as mentioned before.3 0.5% DMSO treated cells were used as the control. 
Effective concentration of the CTB-PIPs was standardized based on the initial optimization experiments and the 
treatment of HDF with various concentration of PI polyamide CTB conjugates (500 nM, 1 µM, 5 µM and 10 µM). 
After 1 µM, no significant effect on the induction pattern was observed by increasing the concentration. Optimization 
studies for incubation time (24 h, 48 h and 72 h) suggested again that 48 h is optimal.  
 
       Microarray analysis and Quantification of gene expression 
       HDFs were treated with 1 µM of effectors and after 48 h incubation total RNA was isolated using RNeasy 
MINI Kit (Qiagen, CA, USA) according to the manufacturer’s instructions. Microarray studies were then carried out 
as mentioned before3 using Human Gene 2.1 ST Array (Affymetrix, USA). The raw data and associated sample 
information were processed by Expression Console (Affymetrix, USA) and Transcriptome Analysis Console 
(Affymetrix, USA). The interpretation of the microarray data is carried out by Ingenuity pathway analysis as 
mentioned before2, 3. Unsupervised clustering analysis was performed using Cluster 3.0 and the results were 
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visualized using Java Treeview as mentioned before3. Fischer’s exact test were employed to measure the p-value that 
determines the association between the genes in the dataset and the library of canonical pathways in the Ingenuity 
pathway knowledge base. For scatter plot analysis, transcripts upregulated in CTB-I-treated HDFs (> 2 fold, p < 0.05 
in comparison with DMSO-treated HDFs) were extracted and plotted against the data obtained in SAHA-I treated 
HDFs. 
Quantification of gene expression was carried using a ReverTra Ace qPCR RT kit (Toyobo, Japan) and real-time 
RT-PCR amplifications were carried out in triplicate with THUNDERBIRD SYBR qPCR Mix (TOYOBO, Japan) 
and analyzed by using ABI 7300 Real-Time PCR System (Applied Biosystems, USA) as mentioned before1-3. The 
relative expression level was calculated using DMSO treated cells as the internal control (1-fold) after normalization 
with GAPDH. Primer pairs used for RT-PCR analysis were as shown before3. The statistical significance was 
determined by the t test. 
 
Chromatin immunoprecipitation sequencing (ChIP-Seq) analysis  
ChIP–PCR was done after immunoprecipitating HDFs treated with CTB-I for 48 h, and the amount of 
promoter sequence of OCT-3/4 in the co-precipitated DNA was measured as before3. ChIP-Seq experiments with an 
H3K14ac-specific antibody were conducted to gain better understanding of CTB-I- mediated acetylation under the 
conditions mentioned before and as follows3. ChIP-Seq libraries were prepared with standard Ion XpressTM Plus 
gDNA Fragment Library Preparation reagents and protocols (Life Technologies, USA) and checked with Agilent 
DNA High sensitivity BioAnalyzer kit (Agilent Technologies, USA). Template preparation with the qualified 
libraries was done using Ion PGMTM template OT2 200 kit and Ion PITM template OT2 200 kit in Ion one touch2 
system. The templates were then enriched in Ion one touch ES and sequenced with Ion PGM sequencer using Ion 
PGMTM sequencing 200 kit v2 / 318 chip and Ion ProtonTM Sequencer using Ion PITM Sequencing 200 kit / Ion PI 
chip by following the manufacturer’s instructions. The data were processed by employing standard program packages 
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in the Ion torrent suit. Torrent Mapping Alignment Program 3.4.3-1 (TMAP) was used for aligning reads, ChIP-seq 
peaks was called using MACS 1.4.24  
 
Cytotoxicity assay 
Colorimetric assays were done as mentioned previously using WST-8 (Dojindo, Kumamoto, Japan) in 
96-well plates with various concentrations of CTB and CTB-I as mentioned before3. 
 
Histone acetyl transferase (HAT) activity assay 
        HAT assay was performed to quantify the HAT activity using HAT Activity Fluorometric Assay Kit 
(BioVision K334-100). Nuclear extracts were collected and purified using Nuclear/Cytosol Fractionation Kit 
(BioVision K266-100). Experiments were carried out using both kits according to the manufacturer’s protocol.  
 
Histone deacetylase (HDAC) activity assay 
        To quantify the HDAC activity, Calorimetric assay was performed using Color de Lys™ kit (BML-AK500) 
according to manufacturers instructions. HDF nuclear extracts were collected using Nuclear/Cytosol Fractionation 












Retention time: 20.03 min 
Figure S1. Mass spectrum and HPLC chromatogram of CTB-I. The purities of the CTB-PIP-I were checked by HPLC 
(elution with 0.1% aqueous solution of trifluoroacetic acid and a linear gradient of 0-100% acetonitrile over 40 min at 









Figure S2. Cytotoxicity assay of (a) CTB and (b) CTB-PIP-I or CTB-I. Cell viability of HDF was measured after 48 












Figure S3. Q-RT-PCR analysis of MIR-302C in the effectors (CTB, CTB-I and SAHA-I) treated HDFs at a 
concentration of 1 µM. Cells treated with 0.5% DMSO were used as the internal standard. Each bar represents the 

















Figure S4. The HAT activity in HDFs individually treated with 1 µM of CTB, CTB-I, CTB-Ne-I and SAHA-I for 48 
h. Nuclear/Cytosol Fractionation Kit (BioVision K266-100) is used to collect and purify the nuclear extract. The 
increase of HAT activity for all samples was determined using HAT Activity Fluorometric Assay Kit (BioVision 
K334-100) after normalizing the values to the untreated HDF cells. 0.5% DMSO-treated cells were used as the 













Figure S5. Enzymatic activity of HAT was tested in the presence of CTB, CTB-I, CTB-Ne-I and SAHA-I for 60 min. 
Each effector was individually treated at three different concentration (500 nM, 1 µM and 2 µM) to HeLa cell nuclear 
extract and the increase in activity is shown by comparing the activity of the extract in the presence of 0.5% DMSO 













Figure S6. Q-RT-PCR analysis of OCT-3/4, SOX2, NANOG, LIN28B. SALL4, EPCAM, ZIC3, DPPA4 and MIR302C 
in HDFs treated with CTB-Ne-I at a concentration of 1 µM. Cells treated with 0.5% DMSO were used as the internal 















Figure S7. HDAC activity in HDFs individually treated with 1 µM of CTB, CTB-I, CTB-Ne-I and SAHA-I for 48 h 
was analyzed using Color de Lys™ kit (BML-AK500). Nuclear extracts collected as shown in Figure S4 was 
incubated (37°C) with 0.2 mM substrate. Reactions were stopped after 30 min. with Color de Lys™ Developer and 











Figure S8. Inhibition of Color de Lys™ Substrate Deacetylation by (a) HeLa Nuclear Extract and (b) HDF nuclear 
extract within Trichostatin A (Black), SAHA (Dark blue), SAHA-I (Light blue), CTB (Dark green), CTB-I (Medium 
green) and CTB-Ne-I (Light green), respectively. Nuclear Extract was incubated as in Figure S7 with indicated 
concentrations of the effectors. Reaction was stopped after 30 min. with Color de Lys™ Developer and the 





Figure S9. Chromatin immunoprecipitation analysis was carried out3 after immunoprecipitation with H3K14Ac 
antibody and the amount of promoter sequence of OCT-3/4 in the co-precipitated DNA was determined by qPCR. 



























Figure S10. ChIP-Seq analysis of the OCT-3/4 regulated pluripotency gene (a) NANOG, (b) SOX2, (c) DPPA4, (d) 








Figure S11. ChIP-Seq analysis of the control genes (a) PIWIL1, (b) HMGB1, (c) TDRD1, and (d) GAPDH was 















Figure S12. Q-RT-PCR analysis of OCT-3/4 in HDFs treated with the combination of CTB-I and SAHA-I at a final 
concentration of 1 µM. Cells treated with 0.5% DMSO were used as the internal standard. Each bar represents the 
































Table S1. Effector modulated genes in human dermal fibroblasts 





















Effectors Up regulated  
Genesa 
Down regulated  
Genesa 
SAHA-I  74  13  
CTB-I 48 19 
CTB  53 45  
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Table S2. Differentially expressed genes in top five pathways in 
 










CTB-I treated HDFs 
Pathway -log(p-value)a Genes 
Role of Oct4 in Mammalian Embryonic 
Stem Cell Pluripotency 
4.07 NANOG, SOX2, NR6A1, IGF2BP1, SALL4, 
POU5F1 
Transcriptional Regulatory Network in 
Embryonic Stem Cells 
3.34 ZIC3, POU5F1, NANOG, SOX2, RFX4 
Embryonic Stem Cell Differentiation 
into Cardiac Lineages 
    3.33 NANOG, SOX2, POU5F1 
Human Embryonic Stem Cell 
Pluripotency 
2.18 SOX2, NANOG, FZD3, FGFR2, SALL4, POU5F1, 
ZIC3 
Autoimmune Thyroid Disease 
Signaling 
2.15 HLA-DQB1, IGHG1, HLA-DQA1, CD40LG, HLA-
DOA, HLA-DRA, IL2 
CTB treated HDFs 
Pathway -log(p-value) Genes 
LXR/RXR Activation 2.46 LYZ, TF, MMP9, SAA4, IL1RAPL2, APOC1, 
IL1RAPL1, IL36G, AMBP, IL1F10 
Nicotine Degradation III 2.35 UGT2B4, UGT2B17, CYP3A4, UGT2A1, CYP3A7, 
CYP1B1 
Melatonin Degradation I 2.23 UGT2B4, UGT2B17, CYP3A4, UGT2A1, CYP3A7, 
CYP1B1 
Superpathway of Melatonin 
Degradation 
2.05 UGT2B4, UGT2B17, CYP3A4, UGT2A1, CYP3A7, 
CYP1B1 
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